A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.
Age ≥ 18 years, gender not specified.
Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathological examination. Patients should test positive for plasma cfDNA before treatment (defined as positive for point mutations, CNV, IgH-related fusion, or IG clonal rearrangement) and achieve complete metabolic remission after 6 cycles of R-CHOP chemotherapy (evaluated by Lugano response assessment criteria).
Patients for whom the researcher predicts a life expectancy of >6 months.
Signed informed consent form.
Patients who have undergone autologous stem cell transplantation.
Patients with a history of other malignant tumors, except for basal cell carcinoma of the skin or in situ cervical cancer.
Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, and other such conditions;
Primary central nervous system lymphoma.